News
Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress.
Medpace delivered a stunning Q2 2025, with double-digit revenue and net new awards growth. Click here to read why MEDP stock ...
KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...
Background The evidence on associations between ultra-processed foods (UPF) and lung cancer risk is limited and inconsistent.
Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 ...
Objective Radiotherapy (RT) can cause a range of negative impacts in addition to the intended treatment impacts. Pulmonary rehabilitation (PR) may improve the physical and psychological conditions of ...
VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...
Minimalist elegance, stunning displays, and quiet operation are among the top features of Dell's new 14' and 16' laptops. - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results